MaryAnne Armstrong, Ph.D., Partner, Birch Stewart Kolasch & Birch, LLP to Speak at KG Event
New York, NY, February 27, 2016 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that MaryAnne Armstrong, Ph.D., Partner will speak at the Knowledge Congress’ webcast entitled: “Effective Intellectual Property Asset Protection for Biotechnology and Biopharmaceutical Facing Subject Matter Eligibility Challenges in 2016 Live Webcast.” This event is scheduled for March 03, 2016 from 12:00pm – 2:00pm (ET).
For further details, please visit:
https://theknowledgegroup.org/event/?ID=effective-intellectual-property-asset-protection-for-biotechnology-and-biopharmaceutical-facing-subject-matter-eligibility-challenges-in-2016-live-webcast-3
About MaryAnne Armstrong
MaryAnne Armstrong is a partner with the law firm Birch, Stewart, Kolasch & Birch, LLP. She has a Ph.D. in biochemistry and master's degree in immunology. Dr. Armstrong works with large and small companies and universities for the preparation and prosecution of patent applications in the fields of immunology, pharmaceutical chemistry, biochemistry, organic chemistry, assay and drug screening systems, medical devices, and plant patents. Dr. Armstrong has considerable experience in counseling clients with regard to FTO opinions, based on infringement and/or validity analysis, as well as counseling clients with regard to patentability analyses and the preparation of license agreements and collaboration agreements. She is also experienced in FDA related procedures, including ANDAs and requests for Patent Term Extension.
About Birch, Stewart, Kolasch and Birch, LLP
Birch, Stewart, Kolasch and Birch, LLP (BSKB) is a full service intellectual property law firm, offering services in the areas of patent prosecution, post-grant review, litigation, ITC litigation, opinions and counseling, design patents, trademarks and licensing. Our knowledgeable attorneys and agents hold advanced degrees and are experienced in the fields of chemistry, electronics and IT, mechanical engineering and life sciences/biotechnology.
We believe in offering every client quality, personalized service, and are committed to educating our clients to help them make the most of their intellectual property. BSKB has a rich tradition of offering seminars on intellectual property law that have been attended by practitioners from around the world.
Event Synopsis:
From the outset, the biotechnology industry has relied upon the patent system to encourage the discovery and development of many innovative products and methods. Recent developments such as bio-markers, companion diagnostics and autologous cell therapies are transforming the treatment of many serious diseases. These advances in biotechnology and pharmacology are expensive and best protected by patents.
However, in the last few years, the United States Supreme Court has limited and reduced the value of biotechnological patents. Recent rulings of the U.S Supreme Court in Mayo v. Prometheus, Assn. for Molecular Pathology v. Myriad Genetics, and Alice Corp. v. CLS Bank have put the biotechnological and biopharmaceutical industries in an uncertain position with the USPTO.
The US judiciary has become increasingly active in defining patent law, and in some instances obscuring the legal intent of Congress. Regarding subject matter eligibility, the only recourse may be to reply upon Congress to revise Section 101 and more clearly define the statutory Subject Matter Eligible for patenting. If Congress allows the courts to more narrowly define subject matter eligibility, some innovations may suffer from inadequate patent protection.
In a two hour, live Webcast, a panel of thought leaders and practitioners assembled by The Knowledge Group will discuss the significant and latest ways to ensure Effective Intellectual Property Asset Protection for Biotechnology and Biopharmaceutical Facing Subject Matter Eligibility Challenges in 2016. The panel of speakers will review the latest cases and offer sound, practical advice in defining the scope of material for protection.
Some of the major topics that will be covered in this course are:
- New Interim Guidance on Patent Subject Matter Eligibility
- IP Protection Strategies
- Prosecution Strategies for Pending Claims
- Drafting New Applications
- Recent Supreme Court Decisions
- Mayo Collaborative Servs. v. Prometheus Labs., Inc.
- Assn. for Molecular Pathology v. Myriad Genetics
- Alice Corp. v. CLS Bank Int'l
- Claims in a Post-Mayo and Post- Myriad Environment
- Litigation Risks
- IP Asset Strategies for Clients
About The Knowledge Group, LLC/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: http://theknowledgegroup.org
For further details, please visit:
https://theknowledgegroup.org/event/?ID=effective-intellectual-property-asset-protection-for-biotechnology-and-biopharmaceutical-facing-subject-matter-eligibility-challenges-in-2016-live-webcast-3
About MaryAnne Armstrong
MaryAnne Armstrong is a partner with the law firm Birch, Stewart, Kolasch & Birch, LLP. She has a Ph.D. in biochemistry and master's degree in immunology. Dr. Armstrong works with large and small companies and universities for the preparation and prosecution of patent applications in the fields of immunology, pharmaceutical chemistry, biochemistry, organic chemistry, assay and drug screening systems, medical devices, and plant patents. Dr. Armstrong has considerable experience in counseling clients with regard to FTO opinions, based on infringement and/or validity analysis, as well as counseling clients with regard to patentability analyses and the preparation of license agreements and collaboration agreements. She is also experienced in FDA related procedures, including ANDAs and requests for Patent Term Extension.
About Birch, Stewart, Kolasch and Birch, LLP
Birch, Stewart, Kolasch and Birch, LLP (BSKB) is a full service intellectual property law firm, offering services in the areas of patent prosecution, post-grant review, litigation, ITC litigation, opinions and counseling, design patents, trademarks and licensing. Our knowledgeable attorneys and agents hold advanced degrees and are experienced in the fields of chemistry, electronics and IT, mechanical engineering and life sciences/biotechnology.
We believe in offering every client quality, personalized service, and are committed to educating our clients to help them make the most of their intellectual property. BSKB has a rich tradition of offering seminars on intellectual property law that have been attended by practitioners from around the world.
Event Synopsis:
From the outset, the biotechnology industry has relied upon the patent system to encourage the discovery and development of many innovative products and methods. Recent developments such as bio-markers, companion diagnostics and autologous cell therapies are transforming the treatment of many serious diseases. These advances in biotechnology and pharmacology are expensive and best protected by patents.
However, in the last few years, the United States Supreme Court has limited and reduced the value of biotechnological patents. Recent rulings of the U.S Supreme Court in Mayo v. Prometheus, Assn. for Molecular Pathology v. Myriad Genetics, and Alice Corp. v. CLS Bank have put the biotechnological and biopharmaceutical industries in an uncertain position with the USPTO.
The US judiciary has become increasingly active in defining patent law, and in some instances obscuring the legal intent of Congress. Regarding subject matter eligibility, the only recourse may be to reply upon Congress to revise Section 101 and more clearly define the statutory Subject Matter Eligible for patenting. If Congress allows the courts to more narrowly define subject matter eligibility, some innovations may suffer from inadequate patent protection.
In a two hour, live Webcast, a panel of thought leaders and practitioners assembled by The Knowledge Group will discuss the significant and latest ways to ensure Effective Intellectual Property Asset Protection for Biotechnology and Biopharmaceutical Facing Subject Matter Eligibility Challenges in 2016. The panel of speakers will review the latest cases and offer sound, practical advice in defining the scope of material for protection.
Some of the major topics that will be covered in this course are:
- New Interim Guidance on Patent Subject Matter Eligibility
- IP Protection Strategies
- Prosecution Strategies for Pending Claims
- Drafting New Applications
- Recent Supreme Court Decisions
- Mayo Collaborative Servs. v. Prometheus Labs., Inc.
- Assn. for Molecular Pathology v. Myriad Genetics
- Alice Corp. v. CLS Bank Int'l
- Claims in a Post-Mayo and Post- Myriad Environment
- Litigation Risks
- IP Asset Strategies for Clients
About The Knowledge Group, LLC/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: http://theknowledgegroup.org
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Categories